Seeking Alpha

Omeros soars on Wedbush OMS302 call

  • Shares of Omeros (OMER +53.2%) skyrocket as Wedbush raises its price target to $28 from $18.
  • Back in August, Liana Moussatos put the odds of the FDA accepting the company's OMS302 NDA for review at 90% (that expectation is reiterated today).
  • After speaking to a "high-volume cataract surgeon," Moussatos has apparently decided to double U.S. penetration estimates for the phenylephrine/ ketorolac combo, developed for the maintenance of pupil dilation, prevention of pupil constriction, and reduction of postoperative ocular pain.
  • The rationale: FDA scrutiny of sterility issues in topical solutions used during intraocular lens replacement surgery should drive up prices on topical NSAIDs and mydriatic agents, making OMS302 price competitive.
Comments (1)
  • Good day for (OMER). Just sold 50% of my holding for a $8K profit.

     

    Will hold the rest for the long term!
    16 Sep 2013, 11:25 AM Reply Like
DJIA (DIA) S&P 500 (SPY)